Mar 21, 2017 11:02 am UTC| Business
WINNIPEG, Manitoba, March 21, 2017 -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce clinical study results which confirm that based on a swab from the inside of...
Mar 21, 2017 11:02 am UTC| Business
WINNIPEG, Manitoba, March 21, 2017 -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce clinical study results which confirm that based on a swab from the inside of...
Mar 21, 2017 11:02 am UTC| Business
OKLAHOMA CITY, March 21, 2017 -- Mammoth Energy Services, Inc. ("Mammoth" or the "Company") (NASDAQ:TUSK) announced today that it has entered into definitive agreements to acquire Sturgeon Acquisitions, LLC (which owns...
Mar 21, 2017 11:02 am UTC| Business
OKLAHOMA CITY, March 21, 2017 -- Mammoth Energy Services, Inc. ("Mammoth" or the "Company") (NASDAQ:TUSK) announced today that it has entered into definitive agreements to acquire Sturgeon Acquisitions, LLC (which owns...
Mar 21, 2017 11:02 am UTC| Business
OKLAHOMA CITY, March 21, 2017 -- Mammoth Energy Services, Inc. ("Mammoth" or the "Company") (NASDAQ:TUSK) announced today that it has entered into definitive agreements to acquire Sturgeon Acquisitions, LLC (which owns...
Mar 21, 2017 11:02 am UTC| Business
- EMA guidance provides clear regulatory pathway for EU approval for Iomab-B - Trial design, primary endpoint and planned statistical analysis from the Iomab-B U.S. pivotal Phase 3 SIERRA trial are acceptable as the...
Mar 21, 2017 11:02 am UTC| Business
- EMA guidance provides clear regulatory pathway for EU approval for Iomab-B - Trial design, primary endpoint and planned statistical analysis from the Iomab-B U.S. pivotal Phase 3 SIERRA trial are acceptable as the...